These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 28799819

  • 1. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA.
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [Abstract] [Full Text] [Related]

  • 2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH, Akhlaghi F.
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [Abstract] [Full Text] [Related]

  • 3. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ.
    Drugs; 2012 Mar 05; 72(4):491-507. PubMed ID: 22356288
    [Abstract] [Full Text] [Related]

  • 4. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD, Klouras E, Barkas F, Elisaf M.
    Expert Rev Cardiovasc Ther; 2016 Aug 05; 14(8):953-62. PubMed ID: 27171534
    [Abstract] [Full Text] [Related]

  • 5. What have we learnt from the clinical outcomes trials with the cetrapibs?
    Doggrell SA.
    Curr Opin Lipidol; 2018 Aug 05; 29(4):327-332. PubMed ID: 29630000
    [Abstract] [Full Text] [Related]

  • 6. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
    Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE, ACCELERATE Investigators.
    N Engl J Med; 2017 May 18; 376(20):1933-1942. PubMed ID: 28514624
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J, Pernický M, Kiňová S.
    Vnitr Lek; 2016 May 18; 62(10):789-794. PubMed ID: 27900865
    [Abstract] [Full Text] [Related]

  • 8. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 May 18; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J, Holmes MV, Preiss D.
    J Am Coll Cardiol; 2019 Feb 05; 73(4):477-487. PubMed ID: 30704580
    [Abstract] [Full Text] [Related]

  • 11. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
    Eyvazian VA, Frishman WH.
    Cardiol Rev; 2017 Feb 05; 25(2):43-52. PubMed ID: 28099220
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
    Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal-Gonzalez S, Sacks FM.
    Arterioscler Thromb Vasc Biol; 2022 Feb 05; 42(2):227-237. PubMed ID: 34937388
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Taheri H, Filion KB, Windle SB, Reynier P, Eisenberg MJ.
    Cardiology; 2020 Feb 05; 145(4):236-250. PubMed ID: 32172237
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ.
    Curr Opin Lipidol; 2013 Jun 05; 24(3):259-64. PubMed ID: 23652567
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.